Insider Trading July 8, 2026 08:24 PM

Puma Biotechnology CFO Executes Stock Sale Under Pre-Arranged Plan

Insider transaction occurs as company reports mixed Q1 results and holds annual shareholder meeting

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
PBYI

Maximo F. Nougues, Chief Financial Officer at Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 9,386 shares of common stock on July 6, 2026, for $77,556 at $8.263 per share. The transaction was part of a Rule 10b5-1(c) sell-to-cover program established December 14, 2020. Post-sale, Nougues holds 230,637 shares directly. PBYI stock trades near its 52-week high of $8.44, up 126% over the past year. InvestingPro analysis suggests undervaluation with significant upside potential. Puma Biotechnology reported Q1 2026 net loss per share of -$0.04 versus forecast $0.00, and revenue of $44.8 million versus $49 million, a -8.57% surprise. The company held its 2026 Annual Meeting of Stockholders, electing eight directors including Alan H. Auerbach, Alessandra Cesano, and Troy E. Wilson for one-year terms until 2027, with some nominees receiving over 37 million shares in favor. Stock data shows PBYI at 8.13 (+0.170, +2.14%) closed at 15:59:59 USD, with after-hours data at 16:10:04. The article includes promotional content for Vision AI risk management and a July sale offer for InvestingPro.

Puma Biotechnology CFO Executes Stock Sale Under Pre-Arranged Plan
PBYI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Puma Biotechnology CFO Maximo Nougues sold 9,386 shares for $77,556 under a pre-existing Rule 10b5-1(c) program, retaining 230,637 shares.
  • PBYI stock has surged 126% over the past year, trading near its 52-week high of $8.44, with analysis suggesting undervaluation.
  • Q1 2026 financial results missed estimates, with a net loss per share of -$0.04 and revenue of $44.8 million, below the $49 million forecast.

Maximo F. Nougues, serving as Chief Financial Officer for Puma Biotechnology, Inc. (NASDAQ:PBYI), completed the sale of 9,386 shares in the company's common stock on July 6, 2026. The transaction resulted in a total value of $77,556, with each share sold at a price point of $8.263.

This divestiture was conducted under the parameters of a Rule 10b5-1(c) sell-to-cover program. The framework for this program was originally adopted on December 14, 2020. Following the execution of this sale, Mr. Nougues maintains a direct holding of 230,637 shares of Puma Biotechnology common stock.

The insider activity occurs against a backdrop of notable price movement for PBYI shares. The stock is currently trading in proximity to its 52-week high of $8.44. Over the preceding twelve-month period, the equity has delivered a return of 126%. Market analysis from InvestingPro indicates that the stock may be undervalued at present levels, with a Fair Value metric suggesting substantial upside potential. Investors seeking detailed valuation and growth analysis can access a comprehensive Pro Research Report, which covers PBYI and over 1,400 additional US equities.

Corporate governance developments accompany the financial reporting cycle. Puma Biotechnology convened its 2026 Annual Meeting of Stockholders. During this assembly, shareholders elected eight directors to serve one-year terms, with the next annual meeting scheduled for 2027. The elected directors include Alan H. Auerbach, Alessandra Cesano, and Troy E. Wilson, among others. Voting tallies demonstrated varied support levels for the nominees, with certain candidates receiving in excess of 37 million shares in favor.

Financial performance for the first quarter of 2026 presented challenges relative to consensus estimates. Puma Biotechnology reported a net loss per share of -$0.04, which fell short of the forecasted $0.00. Revenue for the quarter was recorded at $44.8 million, missing the anticipated figure of $49 million. This discrepancy resulted in a revenue surprise of -8.57%. These financial metrics have drawn attention from market participants.

Market data for PBYI shows the stock closing at 8.13, representing a change of +0.170 or +2.14% at 15:59:59 USD. After-hours trading data recorded at 16:10:04 indicates a price of 8.130 with a change of 0.000 or 0.00%. The equity has experienced volatility, with price points ranging from 7.88 to 8.2 across a one-year timeline.

Investment tools and risk management platforms are available to assist with PBYI trades. Vision AI technology analyzes chart patterns to provide risk management plans, including entry points, stop-loss levels, and profit targets, within a sixty-second timeframe. A promotional offer for a July sale of InvestingPro at 60% off is noted.

Risks

  • Puma Biotechnology's Q1 2026 financial results missed analyst expectations on both earnings and revenue, indicating potential operational or market challenges.
  • The stock's significant 126% return over the past year may expose it to volatility or correction risks, despite undervaluation claims.
  • Investor focus on earnings and revenue surprises highlights sensitivity to financial performance, impacting market confidence in the biotechnology sector.

More from Insider Trading

Lemonade Insurance Executive Offloads $272K in Shares Amid Valuation Shifts Jul 8, 2026 Cuentas CEO Maimon Acquires Shares Amid Financial Restructuring Progress Jul 8, 2026 Airbnb CSO Nathan Blecharczyk Executes Pre-Arranged Share Transactions Jul 8, 2026 MediaAlpha CEO Steven Yi Executes $614K Stock Sale Under Pre-Arranged Plan Jul 8, 2026 MediaAlpha Director Eugene Nonko Executes Multi-Day Stock Divestiture Jul 8, 2026